These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1083 related articles for article (PubMed ID: 31992245)

  • 1. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
    Noh BJ; Kim JH; Eom DW
    Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic implications of immune classification in a multicentre cohort of patients with small intestinal adenocarcinoma.
    Noh BJ; Hong SM; Jun SY; Eom DW
    Pathology; 2020 Feb; 52(2):228-235. PubMed ID: 31685233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The landscape of immune microenvironment in lung adenocarcinoma and squamous cell carcinoma based on PD-L1 expression and tumor-infiltrating lymphocytes.
    Chen L; Cao MF; Zhang X; Dang WQ; Xiao JF; Liu Q; Tan YH; Tan YY; Xu YY; Xu SL; Yao XH; Cui YH; Zhang X; Bian XW
    Cancer Med; 2019 Dec; 8(17):7207-7218. PubMed ID: 31605439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.
    Li Y; Liang L; Dai W; Cai G; Xu Y; Li X; Li Q; Cai S
    Mol Cancer; 2016 Aug; 15(1):55. PubMed ID: 27552968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration.
    Ock CY; Keam B; Kim S; Lee JS; Kim M; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS
    Clin Cancer Res; 2016 May; 22(9):2261-70. PubMed ID: 26819449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer.
    Yagi T; Baba Y; Ishimoto T; Iwatsuki M; Miyamoto Y; Yoshida N; Watanabe M; Baba H
    Ann Surg; 2019 Mar; 269(3):471-478. PubMed ID: 29206673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of programmed cell death-ligand expression in small bowel adenocarcinoma is determined by the tumor microenvironment.
    Hoshimoto A; Tatsuguchi A; Hamakubo R; Nishimoto T; Omori J; Akimoto N; Tanaka S; Fujimori S; Hatori T; Shimizu A; Iwakiri K
    World J Gastroenterol; 2023 Oct; 29(40):5566-5581. PubMed ID: 37970475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type.
    Koh J; Nam SK; Roh H; Kim J; Lee BC; Kim JW; Ahn SH; Park DJ; Kim HH; Park KU; Chung JH; Kim WH; Lee HS
    Genes Chromosomes Cancer; 2019 Jan; 58(1):12-22. PubMed ID: 30239046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The expression of C-MYC in gastric adenocarcinoma is associated with PD-L1 and FOXP3 expression: C-MYC overexpression is a good prognostic factor.
    Won KY; Kim GY; Kim HK; Song MJ; Choi SI; Bae GE; Lim SJ
    Pathol Res Pract; 2019 Nov; 215(11):152639. PubMed ID: 31582185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of CD8-positive tumour-infiltrating lymphocytes and PD-L1 expression in salivary gland cancer.
    Kesar N; Winkelmann R; Oppermann J; Ghanaati S; Martin D; Neumayer T; Balster S; Rödel C; Rödel F; von der Grün J; Balermpas P
    Oral Oncol; 2020 Dec; 111():104931. PubMed ID: 32736208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
    Ko YS; Pyo JS
    Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1/PD-1 crosstalk in colorectal cancer: are we targeting the right cells?
    Cantero-Cid R; Casas-Martin J; Hernández-Jiménez E; Cubillos-Zapata C; Varela-Serrano A; Avendaño-Ortiz J; Casarrubios M; Montalbán-Hernández K; Villacañas-Gil I; Guerra-Pastrián L; Peinado B; Marcano C; Aguirre LA; López-Collazo E
    BMC Cancer; 2018 Oct; 18(1):945. PubMed ID: 30285662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma.
    Patil PA; Blakely AM; Lombardo KA; Machan JT; Miner TJ; Wang LJ; Marwaha AS; Matoso A
    Histopathology; 2018 Jul; 73(1):124-136. PubMed ID: 29489025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
    Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
    Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.